190 patents
Utility
Targeted Delivery of Nicotinaminde Adenine Dinucleotide Salvage Pathway Inhibitors
18 Jan 24
Compounds and compositions are disclosed in which a NAMPT Drug Unit is linked to a targeting Ligand Unit through a Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action.
Christopher Scott Neumann, Kathleen Olivas
Filed: 3 Mar 23
Utility
Glycan-Interacting Compounds and Methods of Use
11 Jan 24
The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer.
Ana Paula Galvao da Silva, Julie DeSander, Jeffrey Behrens, Darius Ghaderi, Mai Zhang, Kristan Meetze
Filed: 7 Nov 22
Utility
Glycan-Interacting Compounds and Methods of Use
4 Jan 24
Methods of treating cancer are provided that include administering glycan-interacting antibodies.
Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
Filed: 7 Nov 22
Utility
Glycan Analysis and Profiling
4 Jan 24
The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies.
Ana Paula Galvao da Silva, Mai Zhang, Darius Ghaderi, Julie DeSander, Jeffrey Behrens, Jillian M. Prendergast
Filed: 28 Feb 23
Utility
Compositions and Methods for Targeting Cancer Stem Cells
4 Jan 24
Compositions and methods for treating ovarian cancer are provided.
David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
Filed: 7 Nov 22
Utility
Compositions and Methods for Targeting Cancer Stem Cells
4 Jan 24
The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.
David A. Eavarone, Julie DeSander, Jeffrey Behrens, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
Filed: 7 Nov 22
Utility
Hydrophobic Auristatin F compounds and conjugates thereof
2 Jan 24
Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities towards nearby cells having lower expression of the moeity targeted by the Conjugate.
Svetlana O. Doronina, Philip Moquist
Filed: 20 Feb 19
Utility
Process for the preparation of pegylated drug-linkers and intermediates thereof
19 Dec 23
The present invention provides improved processes for the preparation of auristatin drug-linkers with a PEG unit, as well as intermediates thereof.
Yunyu Mao, Philip Moquist, Anusuya Choudhury, Wendel Doubleday
Filed: 24 Mar 17
Utility
Treatment of HER2 Positive Cancers
7 Dec 23
In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject.
Scott Peterson, Luke Walker
Filed: 26 Apr 23
Utility
Selective Reduction of Proteins
7 Dec 23
The present invention provides a method for making uncapped cysteine protein preparations, including uncapped engineered cysteine antibody preparations.
Damon L. MEYER
Filed: 26 Apr 23
Utility
Anti-AVB6 antibodies and antibody-drug conjugates
28 Nov 23
Provided are novel anti-αvβ6 antibodies and antibody-drug conjugates and methods of using such anti-αvβ6 antibodies and antibody-drug conjugates to treat cancer.
Maureen Ryan, Lori Westendorf, Eric Bradley Meyer, Heather Jean Kostner
Filed: 4 Dec 20
Utility
Methods of Treating Solid Tumors Driven by HER2 Alterations with Tucatinib In Combination with an ANTI-HER2 Antibody
23 Nov 23
The invention provides methods of treating solid tumors, such as solid tumors with HER2 alterations, e.g., solid tumors in which HER2 is amplified/overexpressed or mutated, with a combination of tucatinib, or salt or solvate thereof, and at least one anti-HER2 antibody, such as trastuzumab or trastuzumab and pertuzumab.
Luke WALKER, Anita KULUKIAN
Filed: 27 Sep 21
Utility
Glypican 3 antibodies and conjugates thereof
21 Nov 23
The invention provides murine, chimeric, and humanized antibodies that specifically bind to GPC3 and conjugates thereof.
Travis Biechele, William Arthur, Patrick Burke, Lori Westendorf
Filed: 15 Feb 19
Utility
Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodies
21 Nov 23
The invention provides methods of treating cancer, such as myeloid malignancies including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), with nonfucosylated anti-CD70 antibodies.
Shyra Gardai, Phoenix Ho
Filed: 28 Dec 20
Utility
Methods for Treating Cancers with Antibody Drug Conjugates (Adc) That Bind to 191P4D12 Proteins
16 Nov 23
Provided herein are methods for treating cancers with antibody drug conjugates (ADC) that bind to 191P4DI2 protein (Nectin-4).
Elaina Marie GARTNER, Eric John CHOWN, Tina KIM-HAFKEN, Dana Ann KENNEDY
Filed: 8 Oct 21
Utility
Antibody Drug Conjugates (Adc) That Bind to 191P4D12 Proteins
2 Nov 23
Antibody drug conjugates (ADC’s) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I.
Daulet SATPAYEV, Robert Kendall MORRISON, Karen Jane Meyrick MORRISON, Jean GUDAS, Aya JAKOBOVITS, Michael TORGOV, Zili AN
Filed: 14 Dec 22
Utility
Conjugates of quaternized tubulysin compounds
24 Oct 23
Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action.
Patrick J. Burke, Joel Courter
Filed: 22 Nov 21
Utility
Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy
24 Oct 23
The present disclosure, relates, in general to methods for improving adverse events in subjects receiving treatment with an anti-CD30 antibody drug conjugate, optionally also receiving accompanying chemotherapy.
Thomas Manley, Neil Josephson
Filed: 11 Oct 18
Utility
Methods for Treating Cancers with Antibody Drug Conjugates (Adc) That Bind to 191P4D12 Proteins
19 Oct 23
Provided herein are methods for the treatment of cancers with antibody drug conjugates (ADC) that bind to 191P4D12 proteins.
Elaina Marie GARTNER
Filed: 16 Sep 21
Utility
Humanized ANTI-LIV1 Antibodies for the Treatment of Cancer
19 Oct 23
Methods for using anti-LIV1 antibodies and antibody-drug conjugates, including anti-LIV1 antibody-drug conjugates, to inhibit proliferation of a cell, such as a LIV1-expressing cell, as well as for the treatment of cancers, such as, e.g., LIV1-associated solid tumors and breast cancer (e.g., locally advanced or metastatic breast cancer), are provided.
Emily STEVENS, Hong LI, William HANLEY, Phillip GARFIN, Shawna HENGEL
Filed: 17 Feb 23